Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

Not Applicable

Terminated

Conditions: Liver Cancer
Hepatocellular Carcinoma

Interventions: Drug: Sorafenib
Radiation: Stereotactic Body Radiotherapy (SBRT)

Registration Number: NCT01005875

Lead Sponsor: University of Alabama at Birmingham

Brief Summary: This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 5

Inclusion Criteria

Child-Pugh class A or B7 cirrhosis.
No prior radiation therapy to the upper right abdominal quadrant.
Size of each tumor less than 6 cm.
Three or less known lesions.
More than 800 cc of uninvolved liver.
Age > 19 years old
ECOG Performance Status 0 or 1
Adequate bone marrow, liver and renal function as assessed by the following:
Hemoglobin > 8.5 g/dl
Platelet count > 50,000/mm3
Total bilirubin < 1.5 times ULN
ALT and AST < 2.5 times the ULN ( < 5 x ULN for patients with liver involvement)
Creatinine < 1.5 times ULN
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men should use adequate birth control for at least three months after the last administration of sorafenib.
Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures.
INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.

Exclusion Criteria

Child-Pugh class B8 or C cirrhosis.
ECOG greater than or equal to 2.
Uncontrolled ascites despite medical management.
Less than 800 cc of uninvolved liver.
Prior radiotherapy to the upper abdominal quadrant.
Prior antiangiogenic or tyrosine kinase inhibitor therapy Cardiac disease: Congestive heart failure > class II NYHA. Patients must not have unstable angina(anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.
Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.
Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure >90 mmHg, despite optimal medical management.
Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
Active clinically serious infection > CTCAE Grade 2.
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.
Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.
Serious non-healing wound, ulcer, or bone fracture.
Evidence or history of bleeding diathesis or coagulopathy
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.
Use of St. John's Wort or rifampin (rifampicin).
Known or suspected allergy to sorafenib or any agent given in the course of this trial.
Any condition that impairs patient's ability to swallow whole pills.
Any malabsorption problem.
Pregnant or lactating female.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Radiation followed by Sorafenib	Sorafenib	Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
Radiation followed by Sorafenib	Stereotactic Body Radiotherapy (SBRT)	Radiation therapy, stereotactic body radiation therapy followed by Sorafenib

Primary Outcome Measures

Name	Time	Method
Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma	between baseline and 3 years	Number of subjects experiencing a Grade 5 toxicity related to SBRT and sorafenib

Secondary Outcome Measures

Name	Time	Method
The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Tumor Volume	baseline, 4 weeks and 10 weeks	mean tumor volume at baseline, 4 weeks and 10 weeks after start of treatment
The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Ktrans (Volume Transfer Coefficient).	baseline, 4 weeks and 10 weeks	The initial mean Ktrans at baseline, 4 weeks and 10 week. K trans is used to describe the uptake of gadolinium contrast in tissue.
The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Kep. Kep Describes How Fast Contrast Can Redistribute in Tissue.	baseline, 4 weeks after baseline and 10 weeks post baseline	The Kep as measures by MRI at baseline, 4 weeks after baseline, and 10 weeks after baseline.
The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).	baseline, 4 weeks post baseline, 10 weeks post baseline	the measured ADC at baseline, 4 weeks after baseline and then 10 weeks after baseline. ADC quantifies the motion of water protons from an MRI.